Drug Profile
AE-M
Alternative Names: AE-08; AE-08 vaccine; AE-M vaccine; Ii-key/gp100Latest Information Update: 03 Feb 2020
Price :
$50
*
At a glance
- Originator Antigen Express
- Developer NuGenerex Immuno-Oncology
- Class Cancer vaccines; Peptide vaccines
- Mechanism of Action Helper-inducer T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 16 Jan 2020 Generex Biotechnology Corporation plans a phase II trial for Malignant-melanoma (Combination therapy) in 2020
- 15 Oct 2019 Generex Biotechnology announces intention to reactivate the melanoma programme by November 2019
- 28 Apr 2018 No recent reports of development identified for phase-I development in Malignant-melanoma in USA (Parenteral)